Inactive Instrument

Highlights Neuralstem, Inc. Nasdaq

Equities

US64127R3021

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 23	Palisade Bio Collaborating With Strand Life Sciences on Ulcerative Colitis Therapy	MT
Apr. 23	Palisade Bio, Inc. Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Palisade Bio, Inc. Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	Apr. 23	CI
Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	Apr. 16	MT
Palisade Bio Shows Bioactivation of PALI-2108 in Study; Shares Rise	Apr. 16	MT
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients? Stool	Apr. 16	CI
Reverse Split: 1 of 15	Apr. 07	FA
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Palisade Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Palisade Bio, Inc. Announces the Appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer	23-09-11	CI
Palisade Bio, Inc. Appoints Mitchell Jones as Chief Medical Officer	23-09-11	CI
Palisade Bio, Inc. Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease	23-09-06	CI
Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Palisade Bio, Inc. Announces Topline Results from U.S. Phase 2 Profile Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions	23-08-09	CI
Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Palisade Bio, Inc. Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study	23-05-11	CI
Palisade Bio, Inc. Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148	23-04-05	CI
Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating Lb1148 for Post-Surgical Abdominal Adhesions	22-12-16	CI
Palisade Bio Secures US FDA's Fast Track Designation for Investigational Drug LB1148	22-11-22	MT
U.S. Food and Drug Administration Grants Fast Track Designation to Palisade Bio for LB1148 for Accelerated Return of Bowel Function Following GI Surgery	22-11-22	CI
Reverse Split: 1 of 50	22-11-15	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Neuralstem, Inc. Nasdaq

Equities

US64127R3021

Highlights

Filters